{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T13:49:41Z","timestamp":1780321781176,"version":"3.54.1"},"reference-count":92,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T00:00:00Z","timestamp":1726012800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T00:00:00Z","timestamp":1726012800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005296","name":"Universit\u00e4tsklinikum Regensburg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005296","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>To support doctors in counselling women with genetic predisposition for breast or gynecologic cancers on endocrine interventions.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Evidence on the safety of endocrine interventions for fertility treatment, contraception, hormone replacement therapy after risk-reducing salpingo-oophorectomy (RRSO) or treatment of symptoms during peri- and postmenopause was analysed for carriers of probably pathogenic and pathogenic variants in <jats:italic>BRCA1<\/jats:italic> or <jats:italic>BRCA2<\/jats:italic> (<jats:italic>BRCA1\/2<\/jats:italic>-pV), in other breast and ovarian cancer genes and the Lynch Syndrome. Cancer risks were compared with data on risks for the general population.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Data on risk modulation of endocrine interventions in women with genetic predisposition is limited. Ovarian hyperstimulation for fertility treatment may be performed. Oral contraceptives should not be used to reduce ovarian cancer risk in <jats:italic>BRCA1\/2<\/jats:italic>-pV carriers. Premenopausal <jats:italic>BRCA1\/2<\/jats:italic>-pV carriers and carriers of pV in Lynch Syndrome genes should be offered hormone replacement therapy (HRT) after RRSO, to prevent diseases caused by estrogen deficiency.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Effect direction and strength of risk modulation by endocrine interventions is similar to the general population. Participation of individuals at risk in prospective registries is recommended.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00432-024-05936-7","type":"journal-article","created":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T13:03:14Z","timestamp":1726059794000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["The risk of endocrine interventions in carriers of a genetic predisposition for breast and gynecologic cancers: recommendations of the German Consortium for Hereditary Breast and Ovarian Cancer"],"prefix":"10.1007","volume":"150","author":[{"given":"O.","family":"Ortmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Sch\u00fcler-Toprak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Kast","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"For The working group \u201cHormones\u201d, The German Consortium for Hereditary Breast, Ovarian Cancer (GC-HBOC)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Fehm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Hahne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Huber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"K\u00fchnle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Mohr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Rhiem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Seitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Speiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,11]]},"reference":[{"key":"5936_CR1","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1001\/jama.291.14.1701","volume":"291","author":"GL Anderson","year":"2004","unstructured":"Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SAA, Black H, Bonds D, Brunner R, Brzyski R, Caan B, Chlebowski R, Curb D, Gass M, Hays J, Heiss G, Hendrix S, Howard BV, Hsia J, Hubbell A, Jackson R, Johnson KC, Judd H, Kotchen JM, Kuller L, LaCroix AZ, Lane D, Langer RD, Lasser N, Lewis CE, Manson J, Margolis K, Ockene J, O\u2019Sullivan MJ, Phillips L, Prentice RL, Ritenbaugh C, Robbins J, Rossouw JE, Sarto G, Stefanick ML, van Horn L, Wactawski-Wende J, Wallace R, Wassertheil-Smoller S (2004) Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women\u2019s Health Initiative randomized controlled trial. JAMA 291:1701\u20131712. https:\/\/doi.org\/10.1001\/jama.291.14.1701","journal-title":"JAMA"},{"key":"5936_CR2","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1002\/ijc.20389","volume":"112","author":"K Bakken","year":"2004","unstructured":"Bakken K, Alsaker E, Eggen AE, Lund E (2004) Hormone replacement therapy and incidence of hormone-dependent cancers in the Norwegian Women and Cancer study. Int J Cancer 112:130\u2013134. https:\/\/doi.org\/10.1002\/ijc.20389","journal-title":"Int J Cancer"},{"key":"5936_CR3","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1002\/ijc.25314","volume":"128","author":"K Bakken","year":"2011","unstructured":"Bakken K, Fournier A, Lund E, Waaseth M, Dumeaux V, Clavel-Chapelon F, Fabre A, H\u00e9mon B, Rinaldi S, Chajes V, Slimani N, Allen NE, Reeves GK, Bingham S, Khaw K-T, Olsen A, Tj\u00f8nneland A, Rodriguez L, S\u00e1nchez M-J, Etxezarreta PA, Ardanaz E, Tormo M-J, Peeters PH, van Gils CH, Steffen A, Schulz M, Chang-Claude J, Kaaks R, Tumino R, Gallo V, Norat T, Riboli E, Panico S, Masala G, Gonz\u00e1lez CA, Berrino F (2011) Menopausal hormone therapy and breast cancer risk: impact of different treatments. The European Prospective Investigation into Cancer and Nutrition. Int J Cancer 128:144\u2013156. https:\/\/doi.org\/10.1002\/ijc.25314","journal-title":"Int J Cancer"},{"key":"5936_CR4","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1093\/humrep\/deaa293","volume":"36","author":"JF Barcroft","year":"2021","unstructured":"Barcroft JF, Galazis N, Jones BP, Getreu N, Bracewell-Milnes T, Grewal KJ, Sorbi F, Yazbek J, Lathouras K, Smith JR, Hardiman P, Thum M-Y, Ben-Nagi J, Ghaem-Maghami S, Verbakel J, Saso S (2021) Fertility treatment and cancers-the eternal conundrum: a systematic review and meta-analysis. Hum Reprod 36:1093\u20131107. https:\/\/doi.org\/10.1093\/humrep\/deaa293","journal-title":"Hum Reprod"},{"key":"5936_CR5","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/s0140-6736(03)14065-2","volume":"362","author":"V Beral","year":"2003","unstructured":"Beral V (2003) Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362:419\u2013427. https:\/\/doi.org\/10.1016\/s0140-6736(03)14065-2","journal-title":"Lancet"},{"key":"5936_CR6","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/S0140-6736(08)60167-1","volume":"371","author":"V Beral","year":"2008","unstructured":"Beral V, Doll R, Hermon C, Peto R, Reeves G (2008) Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet 371:303\u2013314. https:\/\/doi.org\/10.1016\/S0140-6736(08)60167-1","journal-title":"Lancet"},{"key":"5936_CR7","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1016\/s0140-6736(14)61687-1","volume":"385","author":"V Beral","year":"2015","unstructured":"Beral V, Gaitskell K, Hermon C, Moser K, Reeves G, Peto R (2015) Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies. Lancet 385:1835\u20131842. https:\/\/doi.org\/10.1016\/s0140-6736(14)61687-1","journal-title":"Lancet"},{"key":"5936_CR8","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/bjc.2011.202","volume":"105","author":"J Challberg","year":"2011","unstructured":"Challberg J, Ashcroft L, Lalloo F, Eckersley B, Clayton R, Hopwood P, Selby P, Howell A, Evans DG (2011) Menopausal symptoms and bone health in women undertaking risk reducing bilateral salpingo-oophorectomy: significant bone health issues in those not taking HRT. Br J Cancer 105:22\u201327. https:\/\/doi.org\/10.1038\/bjc.2011.202","journal-title":"Br J Cancer"},{"key":"5936_CR9","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1016\/s0140-6736(02)12001-0","volume":"360","author":"N Cherry","year":"2002","unstructured":"Cherry N, Gilmour K, Hannaford P, Heagerty A, Khan MA, Kitchener H, McNamee R, Elstein M, Kay C, Seif M, Buckley H (2002) Oestrogen therapy for prevention of reinfarction in postmenopausal women: a randomised placebo controlled trial. Lancet 360:2001\u20132008. https:\/\/doi.org\/10.1016\/s0140-6736(02)12001-0","journal-title":"Lancet"},{"key":"5936_CR10","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1001\/jama.2020.9482","volume":"324","author":"RT Chlebowski","year":"2020","unstructured":"Chlebowski RT, Anderson GL, Aragaki AK, Manson JE, Stefanick ML, Pan K, Barrington W, Kuller LH, Simon MS, Lane D, Johnson KC, Rohan TE, Gass MLS, Cauley JA, Paskett ED, Sattari M, Prentice RL (2020) Association of menopausal hormone therapy with breast cancer incidence and mortality during long-term follow-up of the women\u2019s health initiative randomized clinical trials. JAMA 324:369\u2013380. https:\/\/doi.org\/10.1001\/jama.2020.9482","journal-title":"JAMA"},{"key":"5936_CR11","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1093\/humupd\/dmq022","volume":"16","author":"D Cibula","year":"2010","unstructured":"Cibula D, Gompel A, Mueck AO, La Vecchia C, Hannaford PC, Skouby SO, Zikan M, Dusek L (2010) Hormonal contraception and risk of cancer. Hum Reprod Update 16:631\u2013650. https:\/\/doi.org\/10.1093\/humupd\/dmq022","journal-title":"Hum Reprod Update"},{"key":"5936_CR12","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1586\/era.11.38","volume":"11","author":"D Cibula","year":"2011","unstructured":"Cibula D, Zikan M, Dusek L, Majek O (2011) Oral contraceptives and risk of ovarian and breast cancers in BRCA mutation carriers: a meta-analysis. Expert Rev Anticancer Ther 11:1197\u20131207. https:\/\/doi.org\/10.1586\/era.11.38","journal-title":"Expert Rev Anticancer Ther"},{"key":"5936_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.mri.2012.06.022","volume":"31","author":"TV Clendenen","year":"2013","unstructured":"Clendenen TV, Kim S, Moy L, Wan L, Rusinek H, Stanczyk FZ, Pike MC, Zeleniuch-Jacquotte A (2013) Magnetic resonance imaging (MRI) of hormone-induced breast changes in young premenopausal women. Magn Reson Imaging 31:1\u20139. https:\/\/doi.org\/10.1016\/j.mri.2012.06.022","journal-title":"Magn Reson Imaging"},{"key":"5936_CR14","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/BF00051356","volume":"3","author":"GA Colditz","year":"1992","unstructured":"Colditz GA, Stampfer MJ, Willett WC, Hunter DJ, Manson JE, Hennekens CH, Rosner BA, Speizer FE (1992) Type of postmenopausal hormone use and risk of breast cancer: 12-year follow-up from the Nurses\u2019 Health Study. Cancer Causes Control 3:433\u2013439. https:\/\/doi.org\/10.1007\/BF00051356","journal-title":"Cancer Causes Control"},{"key":"5936_CR15","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1016\/S0140-6736(19)31709-X","volume":"394","author":"Collaborative Group on Hormonal Factors in Breast Cancer","year":"2019","unstructured":"Collaborative Group on Hormonal Factors in Breast Cancer (2019) Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. Lancet 394:1159\u20131168. https:\/\/doi.org\/10.1016\/S0140-6736(19)31709-X","journal-title":"Lancet"},{"key":"5936_CR16","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1016\/s0140-6736(96)90806-5","volume":"347","author":"Collaborative Group on Hormonal Factors in Breast Cancer","year":"1996","unstructured":"Collaborative Group on Hormonal Factors in Breast Cancer, van den Brandt PA, Goldbohm RA (1996) Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet 347:1713\u20131727. https:\/\/doi.org\/10.1016\/s0140-6736(96)90806-5","journal-title":"Lancet"},{"key":"5936_CR17","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.ejca.2016.11.028","volume":"72","author":"MM de Jonge","year":"2017","unstructured":"de Jonge MM, Mooyaart AL, Vreeswijk MPG, de Kroon CD, van Wezel T, van Asperen CJ, Smit VTHBM, Dekkers OM, Bosse T (2017) Linking uterine serous carcinoma to BRCA1\/2-associated cancer syndrome: a meta-analysis and case report. Eur J Cancer 72:215\u2013225. https:\/\/doi.org\/10.1016\/j.ejca.2016.11.028","journal-title":"Eur J Cancer"},{"key":"5936_CR18","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41436-019-0596-9","volume":"22","author":"M Dominguez-Valentin","year":"2020","unstructured":"Dominguez-Valentin M, Sampson JR, Sepp\u00e4l\u00e4 TT, ten Broeke SW, Plazzer J-P, Nakken S, Engel C, Aretz S, Jenkins MA, Sunde L, Bernstein I, Capella G, Balaguer F, Thomas H, Evans DG, Burn J, Greenblatt M, Hovig E, de Vos Tot Nederveen Cappel WH, Sijmons RH, Bertario L, Tibiletti MG, Cavestro GM, Lindblom A, Della Valle A, Lopez-K\u00f6stner F, Gluck N, Katz LH, Heinimann K, Vaccaro CA, B\u00fcttner R, G\u00f6rgens H, Holinski-Feder E, Morak M, Holzapfel S, H\u00fcneburg R, von Knebel Doeberitz M, Loeffler M, Rahner N, Schackert HK, Steinke-Lange V, Schmiegel W, Vangala D, Pylv\u00e4n\u00e4inen K, Renkonen-Sinisalo L, Hopper JL, Win AK, Haile RW, Lindor NM, Gallinger S, Le Marchand L, Newcomb PA, Figueiredo JC, Thibodeau SN, Wadt K, Therkildsen C, Okkels H, Ketabi Z, Moreira L, S\u00e1nchez A, Serra-Burriel M, Pineda M, Navarro M, Blanco I, Green K, Lalloo F, Crosbie EJ, Hill J, Denton OG, Frayling IM, R\u00f8dland EA, Vasen H, Mints M, Neffa F, Esperon P, Alvarez K, Kariv R, Rosner G, Pinero TA, Gonzalez ML, Kalfayan P, Tjandra D, Winship IM, Macrae F, M\u00f6slein G, Mecklin J-P, Nielsen M, M\u00f8ller P (2020) Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the prospective Lynch syndrome database. Genet Med 22:15\u201325. https:\/\/doi.org\/10.1038\/s41436-019-0596-9","journal-title":"Genet Med"},{"key":"5936_CR19","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007245.pub3","author":"S Dominick","year":"2015","unstructured":"Dominick S, Hickey M, Chin J, Su HI (2015) Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD007245.pub3","journal-title":"Cochrane Database Syst Rev"},{"key":"5936_CR20","doi-asserted-by":"publisher","first-page":"483","DOI":"10.3109\/13697137.2015.1020484","volume":"18","author":"SS Faubion","year":"2015","unstructured":"Faubion SS, Kuhle CL, Shuster LT, Rocca WA (2015) Long-term health consequences of premature or early menopause and considerations for management. Climacteric 18:483\u2013491. https:\/\/doi.org\/10.3109\/13697137.2015.1020484","journal-title":"Climacteric"},{"key":"5936_CR21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1004188","volume":"20","author":"D Fitzpatrick","year":"2023","unstructured":"Fitzpatrick D, Pirie K, Reeves G, Green J, Beral V (2023) Combined and progestagen-only hormonal contraceptives and breast cancer risk: a UK nested case-control study and meta-analysis. PLoS Med 20:e1004188. https:\/\/doi.org\/10.1371\/journal.pmed.1004188","journal-title":"PLoS Med"},{"key":"5936_CR22","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1002\/ijc.20710","volume":"114","author":"A Fournier","year":"2005","unstructured":"Fournier A, Berrino F, Riboli E, Avenel V, Clavel-Chapelon F (2005) Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. Int J Cancer 114:448\u2013454. https:\/\/doi.org\/10.1002\/ijc.20710","journal-title":"Int J Cancer"},{"key":"5936_CR23","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s10549-007-9523-x","volume":"107","author":"A Fournier","year":"2008","unstructured":"Fournier A, Berrino F, Clavel-Chapelon F (2008) Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat 107:103\u2013111. https:\/\/doi.org\/10.1007\/s10549-007-9523-x","journal-title":"Breast Cancer Res Treat"},{"key":"5936_CR24","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.bpobgyn.2020.01.006","volume":"65","author":"F Gaba","year":"2020","unstructured":"Gaba F, Manchanda R (2020) Systematic review of acceptability, cardiovascular, neurological, bone health and HRT outcomes following risk reducing surgery in BRCA carriers. Best Pract Res Clin Obstet Gynaecol 65:46\u201365. https:\/\/doi.org\/10.1016\/j.bpobgyn.2020.01.006","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"5936_CR25","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s13058-020-01332-4","volume":"22","author":"M Gabrielson","year":"2020","unstructured":"Gabrielson M, Azam S, Hardell E, Holm M, Ubhayasekera KA, Eriksson M, B\u00e4cklund M, Bergquist J, Czene K, Hall P (2020) Hormonal determinants of mammographic density and density change. Breast Cancer Res 22:95. https:\/\/doi.org\/10.1186\/s13058-020-01332-4","journal-title":"Breast Cancer Res"},{"key":"5936_CR26","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.psyneuen.2019.03.013","volume":"106","author":"MK Georgakis","year":"2019","unstructured":"Georgakis MK, Beskou-Kontou T, Theodoridis I, Skalkidou A, Petridou ET (2019) Surgical menopause in association with cognitive function and risk of dementia: a systematic review and meta-analysis. Psychoneuroendocrinology 106:9\u201319. https:\/\/doi.org\/10.1016\/j.psyneuen.2019.03.013","journal-title":"Psychoneuroendocrinology"},{"key":"5936_CR27","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/j.fertnstert.2015.11.034","volume":"105","author":"J Gronwald","year":"2016","unstructured":"Gronwald J, Glass K, Rosen B, Karlan B, Tung N, Neuhausen SL, Moller P, Ainsworth P, Sun P, Narod SA, Lubinski J, Kotsopoulos J (2016) Treatment of infertility does not increase the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation. Fertil Steril 105:781\u2013785. https:\/\/doi.org\/10.1016\/j.fertnstert.2015.11.034","journal-title":"Fertil Steril"},{"key":"5936_CR28","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c927","volume":"340","author":"PC Hannaford","year":"2010","unstructured":"Hannaford PC, Iversen L, Macfarlane TV, Elliott AM, Angus V, Lee AJ (2010) Mortality among contraceptive pill users: cohort evidence from Royal College of General Practitioners\u2019 Oral Contraception Study. BMJ 340:c927. https:\/\/doi.org\/10.1136\/bmj.c927","journal-title":"BMJ"},{"key":"5936_CR29","doi-asserted-by":"publisher","first-page":"939","DOI":"10.7326\/0003-4819-135-11-200112040-00005","volume":"135","author":"HN Hodis","year":"2001","unstructured":"Hodis HN, Mack WJ, Lobo RA, Shoupe D, Sevanian A, Mahrer PR, Selzer RH, Liu Cr CR, Liu Ch CH, Azen SP (2001) Estrogen in the prevention of atherosclerosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 135:939\u2013953. https:\/\/doi.org\/10.7326\/0003-4819-135-11-200112040-00005","journal-title":"Ann Intern Med"},{"key":"5936_CR30","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1007\/s00404-020-05690-4","volume":"302","author":"D Huber","year":"2020","unstructured":"Huber D, Seitz S, Kast K, Emons G, Ortmann O (2020a) Use of fertility treatments in BRCA1\/2 mutation carriers and risk for ovarian and breast cancer: a systematic review. Arch Gynecol Obstet 302:715\u2013720. https:\/\/doi.org\/10.1007\/s00404-020-05690-4","journal-title":"Arch Gynecol Obstet"},{"key":"5936_CR31","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1007\/s00404-020-05458-w","volume":"301","author":"D Huber","year":"2020","unstructured":"Huber D, Seitz S, Kast K, Emons G, Ortmann O (2020b) Use of oral contraceptives in BRCA mutation carriers and risk for ovarian and breast cancer: a systematic review. Arch Gynecol Obstet 301:875\u2013884. https:\/\/doi.org\/10.1007\/s00404-020-05458-w","journal-title":"Arch Gynecol Obstet"},{"key":"5936_CR32","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1007\/s00432-021-03629-z","volume":"147","author":"D Huber","year":"2021","unstructured":"Huber D, Seitz S, Kast K, Emons G, Ortmann O (2021) Hormone replacement therapy in BRCA mutation carriers and risk of ovarian, endometrial, and breast cancer: a systematic review. J Cancer Res Clin Oncol 147:2035\u20132045. https:\/\/doi.org\/10.1007\/s00432-021-03629-z","journal-title":"J Cancer Res Clin Oncol"},{"key":"5936_CR33","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b249","volume":"338","author":"A Jensen","year":"2009","unstructured":"Jensen A, Sharif H, Frederiksen K, Kjaer SK (2009) Use of fertility drugs and risk of ovarian cancer: Danish Population Based Cohort Study. BMJ 338:b249. https:\/\/doi.org\/10.1136\/bmj.b249","journal-title":"BMJ"},{"key":"5936_CR34","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s00432-015-2035-x","volume":"142","author":"R Kessous","year":"2016","unstructured":"Kessous R, Davidson E, Meirovitz M, Sergienko R, Sheiner E (2016) The risk of female malignancies after fertility treatments: a cohort study with 25-year follow-up. J Cancer Res Clin Oncol 142:287\u2013293. https:\/\/doi.org\/10.1007\/s00432-015-2035-x","journal-title":"J Cancer Res Clin Oncol"},{"key":"5936_CR35","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1210\/jc.2015-3878","volume":"101","author":"J Kim","year":"2016","unstructured":"Kim J, Turan V, Oktay K (2016) Long-term safety of letrozole and gonadotropin stimulation for fertility preservation in women with breast cancer. J Clin Endocrinol Metab 101:1364\u20131371. https:\/\/doi.org\/10.1210\/jc.2015-3878","journal-title":"J Clin Endocrinol Metab"},{"key":"5936_CR36","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.ygyno.2005.07.110","volume":"100","author":"J Kotsopoulos","year":"2006","unstructured":"Kotsopoulos J, Lubinski J, Neuhausen SL, Lynch HT, Rosen B, Ainsworth P, Moller P, Ghadirian P, Isaacs C, Karlan B, Sun P, Narod SA (2006) Hormone replacement therapy and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. Gynecol Oncol 100:83\u201388. https:\/\/doi.org\/10.1016\/j.ygyno.2005.07.110","journal-title":"Gynecol Oncol"},{"key":"5936_CR37","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1007\/s10552-008-9175-0","volume":"19","author":"J Kotsopoulos","year":"2008","unstructured":"Kotsopoulos J, Librach CL, Lubinski J, Gronwald J, Kim-Sing C, Ghadirian P, Lynch HT, Moller P, Foulkes WD, Randall S, Manoukian S, Pasini B, Tung N, Ainsworth PJ, Cummings S, Sun P, Narod SA (2008) Infertility, treatment of infertility, and the risk of breast cancer among women with BRCA1 and BRCA2 mutations: a case-control study. Cancer Causes Control 19:1111\u20131119. https:\/\/doi.org\/10.1007\/s10552-008-9175-0","journal-title":"Cancer Causes Control"},{"key":"5936_CR38","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s10549-016-3685-3","volume":"155","author":"J Kotsopoulos","year":"2016","unstructured":"Kotsopoulos J, Huzarski T, Gronwald J, Moller P, Lynch HT, Neuhausen SL, Senter L, Demsky R, Foulkes WD, Eng C, Karlan B, Tung N, Singer CF, Sun P, Lubinski J, Narod SA (2016) Hormone replacement therapy after menopause and risk of breast cancer in BRCA1 mutation carriers: a case-control study. Breast Cancer Res Treat 155:365\u2013373. https:\/\/doi.org\/10.1007\/s10549-016-3685-3","journal-title":"Breast Cancer Res Treat"},{"key":"5936_CR39","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1001\/jamaoncol.2018.0211","volume":"4","author":"J Kotsopoulos","year":"2018","unstructured":"Kotsopoulos J, Gronwald J, Karlan BY, Huzarski T, Tung N, Moller P, Armel S, Lynch HT, Senter L, Eisen A, Singer CF, Foulkes WD, Jacobson MR, Sun P, Lubinski J, Narod SA (2018) Hormone replacement therapy after oophorectomy and breast cancer risk among BRCA1 mutation carriers. JAMA Oncol 4:1059\u20131065. https:\/\/doi.org\/10.1001\/jamaoncol.2018.0211","journal-title":"JAMA Oncol"},{"key":"5936_CR40","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1002\/cncr.31842","volume":"125","author":"Y Laitman","year":"2019","unstructured":"Laitman Y, Michaelson-Cohen R, Levi E, Chen-Shtoyerman R, Reish O, Josefsberg Ben-Yehoshua S, Bernstein-Molho R, Keinan-Boker L, Rosengarten O, Silverman BG, Perri T, Korach J, Mor P, Ephrat Ben-Baruch N, Levy Lahad E, Friedman E (2019) Uterine cancer in Jewish Israeli BRCA1\/2 mutation carriers. Cancer 125:698\u2013703. https:\/\/doi.org\/10.1002\/cncr.31842","journal-title":"Cancer"},{"key":"5936_CR41","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/s0749-3797(99)00078-1","volume":"17","author":"JF Lando","year":"1999","unstructured":"Lando JF, Heck KE, Brett KM (1999) Hormone replacement therapy and breast cancer risk in a nationally representative cohort. Am J Prev Med 17:176\u2013180. https:\/\/doi.org\/10.1016\/s0749-3797(99)00078-1","journal-title":"Am J Prev Med"},{"key":"5936_CR42","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1038\/s41436-018-0406-9","volume":"21","author":"A Lee","year":"2019","unstructured":"Lee A, Mavaddat N, Wilcox AN, Cunningham AP, Carver T, Hartley S, Babb de Villiers C, Izquierdo A, Simard J, Schmidt MK, Walter FM, Chatterjee N, Garcia-Closas M, Tischkowitz M, Pharoah P, Easton DF, Antoniou AC (2019) BOADICEA: a comprehensive breast cancer risk prediction model incorporating genetic and nongenetic risk factors. Genet Med 21:1708\u20131718. https:\/\/doi.org\/10.1038\/s41436-018-0406-9","journal-title":"Genet Med"},{"key":"5936_CR43","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.986477","volume":"13","author":"X Liu","year":"2022","unstructured":"Liu X, Yue J, Pervaiz R, Zhang H, Wang L (2022) Association between fertility treatments and breast cancer risk in women with a family history or BRCA mutations: a systematic review and meta-analysis. Front Endocrinol (Lausanne) 13:986477. https:\/\/doi.org\/10.3389\/fendo.2022.986477","journal-title":"Front Endocrinol (Lausanne)"},{"key":"5936_CR44","doi-asserted-by":"publisher","first-page":"1131251","DOI":"10.3389\/fcvm.2023.1131251","volume":"10","author":"J Liu","year":"2023","unstructured":"Liu J, Jin X, Liu W, Chen W, Wang L, Feng Z, Huang J (2023) The risk of long-term cardiometabolic disease in women with premature or early menopause: a systematic review and meta-analysis. Front Cardiovasc Med 10:1131251. https:\/\/doi.org\/10.3389\/fcvm.2023.1131251","journal-title":"Front Cardiovasc Med"},{"key":"5936_CR45","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1002\/ijc.22699","volume":"121","author":"E Lund","year":"2007","unstructured":"Lund E, Bakken K, Dumeaux V, Andersen V, Kumle M (2007) Hormone replacement therapy and breast cancer in former users of oral contraceptives\u2013The Norwegian Women and Cancer study. Int J Cancer 121:645\u2013648. https:\/\/doi.org\/10.1002\/ijc.22699","journal-title":"Int J Cancer"},{"key":"5936_CR46","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1097\/EDE.0b013e31816334c5","volume":"19","author":"G Lurie","year":"2008","unstructured":"Lurie G, Wilkens LR, Thompson PJ, McDuffie KE, Carney ME, Terada KY, Goodman MT (2008) Combined oral contraceptive use and epithelial ovarian cancer risk: time-related effects. Epidemiology 19:237\u2013243. https:\/\/doi.org\/10.1097\/EDE.0b013e31816334c5","journal-title":"Epidemiology"},{"key":"5936_CR47","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1001\/jama.2013.278040","volume":"310","author":"JE Manson","year":"2013","unstructured":"Manson JE, Chlebowski RT, Stefanick ML, Aragaki AK, Rossouw JE, Prentice RL, Anderson G, Howard BV, Thomson CA, LaCroix AZ, Wactawski-Wende J, Jackson RD, Limacher M, Margolis KL, Wassertheil-Smoller S, Beresford SA, Cauley JA, Eaton CB, Gass M, Hsia J, Johnson KC, Kooperberg C, Kuller LH, Lewis CE, Liu S, Martin LW, Ockene JK, O\u2019Sullivan MJ, Powell LH, Simon MS, van Horn L, Vitolins MZ, Wallace RB (2013) Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women\u2019s Health Initiative randomized trials. JAMA 310:1353\u20131368. https:\/\/doi.org\/10.1001\/jama.2013.278040","journal-title":"JAMA"},{"key":"5936_CR48","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.critrevonc.2018.09.018","volume":"132","author":"C Marchetti","year":"2018","unstructured":"Marchetti C, de Felice F, Boccia S, Sassu C, Di Donato V, Perniola G, Palaia I, Monti M, Muzii L, Tombolini V, Benedetti Panici P (2018) Hormone replacement therapy after prophylactic risk-reducing salpingo-oophorectomy and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a meta-analysis. Crit Rev Oncol Hematol 132:111\u2013115. https:\/\/doi.org\/10.1016\/j.critrevonc.2018.09.018","journal-title":"Crit Rev Oncol Hematol"},{"key":"5936_CR49","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1158\/1055-9965.EPI-06-0034","volume":"15","author":"VA McCormack","year":"2006","unstructured":"McCormack VA, dos Santos SI (2006) Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev 15:1159\u20131169. https:\/\/doi.org\/10.1158\/1055-9965.EPI-06-0034","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"5936_CR50","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.ejca.2021.02.007","volume":"148","author":"R Michaelson-Cohen","year":"2021","unstructured":"Michaelson-Cohen R, Gabizon-Peretz S, Armon S, Srebnik-Moshe N, Mor P, Tomer A, Levy-Lahad E, Paluch-Shimon S (2021) Breast cancer risk and hormone replacement therapy among BRCA carriers after risk-reducing salpingo-oophorectomy. Eur J Cancer 148:95\u2013102. https:\/\/doi.org\/10.1016\/j.ejca.2021.02.007","journal-title":"Eur J Cancer"},{"key":"5936_CR51","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1093\/aje\/kwn006","volume":"167","author":"PG Moorman","year":"2008","unstructured":"Moorman PG, Calingaert B, Palmieri RT, Iversen ES, Bentley RC, Halabi S, Berchuck A, Schildkraut JM (2008) Hormonal risk factors for ovarian cancer in premenopausal and postmenopausal women. Am J Epidemiol 167:1059\u20131069. https:\/\/doi.org\/10.1093\/aje\/kwn006","journal-title":"Am J Epidemiol"},{"key":"5936_CR52","doi-asserted-by":"publisher","first-page":"4188","DOI":"10.1200\/JCO.2013.48.9021","volume":"31","author":"PG Moorman","year":"2013","unstructured":"Moorman PG, Havrilesky LJ, Gierisch JM, Coeytaux RR, Lowery WJ, Peragallo Urrutia R, Dinan M, McBroom AJ, Hasselblad V, Sanders GD, Myers ER (2013) Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: a systematic review and meta-analysis. J Clin Oncol 31:4188\u20134198. https:\/\/doi.org\/10.1200\/JCO.2013.48.9021","journal-title":"J Clin Oncol"},{"key":"5936_CR53","doi-asserted-by":"publisher","first-page":"2228","DOI":"10.1056\/NEJMoa1700732","volume":"377","author":"LS M\u00f8rch","year":"2017","unstructured":"M\u00f8rch LS, Skovlund CW, Hannaford PC, Iversen L, Fielding S, Lidegaard \u00d8 (2017) Contemporary hormonal contraception and the risk of breast cancer. N Engl J Med 377:2228\u20132239. https:\/\/doi.org\/10.1056\/NEJMoa1700732","journal-title":"N Engl J Med"},{"key":"5936_CR54","doi-asserted-by":"publisher","DOI":"10.1530\/ey.15.15.9","author":"LS M\u00f8rch","year":"2018","unstructured":"M\u00f8rch LS, Skovlund CW, Hannaford PC, Iversen L, Fielding S, Lidegaard O (2018) Contemporary hormonal contraception and the risk of breast cancer. ESPE. https:\/\/doi.org\/10.1530\/ey.15.15.9","journal-title":"ESPE"},{"key":"5936_CR55","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1097\/AOG.0b013e3181a11c64","volume":"113","author":"WH Parker","year":"2009","unstructured":"Parker WH, Broder MS, Chang E, Feskanich D, Farquhar C, Liu Z, Shoupe D, Berek JS, Hankinson S, Manson JE (2009) Ovarian conservation at the time of hysterectomy and long-term health outcomes in the nurses\u2019 health study. Obstet Gynecol 113:1027\u20131037. https:\/\/doi.org\/10.1097\/AOG.0b013e3181a11c64","journal-title":"Obstet Gynecol"},{"key":"5936_CR56","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1097\/AOG.0b013e3182864350","volume":"121","author":"WH Parker","year":"2013","unstructured":"Parker WH, Feskanich D, Broder MS, Chang E, Shoupe D, Farquhar CM, Berek JS, Manson JE (2013) Long-term mortality associated with oophorectomy compared with ovarian conservation in the nurses\u2019 health study. Obstet Gynecol 121:709\u2013716. https:\/\/doi.org\/10.1097\/AOG.0b013e3182864350","journal-title":"Obstet Gynecol"},{"key":"5936_CR57","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1016\/j.fertnstert.2015.02.011","volume":"103","author":"T Perri","year":"2015","unstructured":"Perri T, Lifshitz D, Sadetzki S, Oberman B, Meirow D, Ben-Baruch G, Friedman E, Korach J (2015) Fertility treatments and invasive epithelial ovarian cancer risk in Jewish Israeli BRCA1 or BRCA2 mutation carriers. Fertil Steril 103:1305\u20131312. https:\/\/doi.org\/10.1016\/j.fertnstert.2015.02.011","journal-title":"Fertil Steril"},{"issue":"2","key":"5936_CR92","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/j.fertnstert.2021.02.030","volume":"116","author":"T Perri","year":"2021","unstructured":"Perri T, Naor-Revel S, Eliassi-Revivo P, Lifshitz D, Friedman E, Korach J (2021) Fertility treatments and breast cancer risk in Jewish Israeli BRCA mutation carriers. Fertil Steril 116(2):538\u2013545. https:\/\/doi.org\/10.1016\/j.fertnstert.2021.02.030","journal-title":"Fertil Steril"},{"key":"5936_CR58","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1093\/aje\/kwp115","volume":"170","author":"RL Prentice","year":"2009","unstructured":"Prentice RL, Manson JE, Langer RD, Anderson GL, Pettinger M, Jackson RD, Johnson KC, Kuller LH, Lane DS, Wactawski-Wende J, Brzyski R, Allison M, Ockene J, Sarto G, Rossouw JE (2009) Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause. Am J Epidemiol 170:12\u201323. https:\/\/doi.org\/10.1093\/aje\/kwp115","journal-title":"Am J Epidemiol"},{"key":"5936_CR59","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/aje\/kwaa210","volume":"190","author":"RL Prentice","year":"2021","unstructured":"Prentice RL, Aragaki AK, Chlebowski RT, Rossouw JE, Anderson GL, Stefanick ML, Wactawski-Wende J, Kuller LH, Wallace R, Johnson KC, Shadyab AH, Gass M, Manson JE (2021) Randomized trial evaluation of the benefits and risks of menopausal hormone therapy among women 50\u201359 years of age. Am J Epidemiol 190:365\u2013375. https:\/\/doi.org\/10.1093\/aje\/kwaa210","journal-title":"Am J Epidemiol"},{"key":"5936_CR60","doi-asserted-by":"publisher","first-page":"7804","DOI":"10.1200\/JCO.2004.00.8151","volume":"23","author":"TR Rebbeck","year":"2005","unstructured":"Rebbeck TR, Friebel T, Wagner T, Lynch HT, Garber JE, Daly MB, Isaacs C, Olopade OI, Neuhausen SL, van Veer \u2018t L, Eeles R, Evans DG, Tomlinson G, Matloff E, Narod SA, Eisen A, Domchek S, Armstrong K, Weber BL (2005) Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 23:7804\u20137810. https:\/\/doi.org\/10.1200\/JCO.2004.00.8151","journal-title":"J Clin Oncol"},{"key":"5936_CR61","doi-asserted-by":"publisher","first-page":"CD008215","DOI":"10.1002\/14651858.CD008215.pub3","volume":"6","author":"I Rizzuto","year":"2019","unstructured":"Rizzuto I, Behrens RF, Smith LA (2019) Risk of ovarian cancer in women treated with ovarian stimulating drugs for infertility. Cochrane Database Syst Rev. 6:CD008215. https:\/\/doi.org\/10.1002\/14651858.CD008215.pub3","journal-title":"Cochrane Database Syst Rev."},{"key":"5936_CR62","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/S1470-2045(06)70869-5","volume":"7","author":"WA Rocca","year":"2006","unstructured":"Rocca WA, Grossardt BR, de Andrade M, Malkasian GD, Melton LJ (2006) Survival patterns after oophorectomy in premenopausal women: a population-based cohort study. Lancet Oncol 7:821\u2013828. https:\/\/doi.org\/10.1016\/S1470-2045(06)70869-5","journal-title":"Lancet Oncol"},{"key":"5936_CR63","unstructured":"SS3-Guideline \u201cDiagnosis, Treatment and Follow-up of malignant Ovarian Tumors\u201d: AWMF-Registrynumber: 032\/035, long version. https:\/\/www.leitlinienprogramm-onkologie.de\/fileadmin\/user_upload\/LL_Ovarialkarzinom_Langversion_5.1.pdf. Accessed 26 March 2024"},{"key":"5936_CR64","unstructured":"S3-Guideline \u201cEndometrial Cancer\u201d: AWMF-Registrynumber 032\/034-OL, long version 2.0, September 2022. https:\/\/www.leitlinienprogramm-onkologie.de\/fileadmin\/user_upload\/Downloads\/Leitlinien\/Endometriumkarzinom\/Version_2\/LL_Endometriumkarzinom_Langversion_2.0.pdf. Accessed 3 May 2024"},{"key":"5936_CR65","unstructured":"S3-Guideline \u201cHormonal Contraception\u201d: AWMF-Registrynumber 015\/015, September 2020, Version 1.2. https:\/\/register.awmf.org\/assets\/guidelines\/015-015l_S3_Hormonelle_Empfaengnisverhuetung_2020-09.pdf. Accessed 3 May 2024"},{"key":"5936_CR66","unstructured":"S3-Guideline \u201cPeri- and Postmenopause\u2014Diagnosis and Interventions: Guideline of the German Society of Gynecology and Obstetrics (S-3 Level, AWMF Registry No. 015\u2013062); October 2018. http:\/\/www.awmf.org\/leitlinien\/detail\/ll\/015-062.html. Accessed 27 November 2021"},{"key":"5936_CR67","unstructured":"S3-Guideline \u201cScreening, Diagnosis, Treatment and Follow-up of Breast Cancer\u201d: AWMF-Registrynumber: 032\u2013045, long version, Version 4.4, June 2021. https:\/\/register.awmf.org\/assets\/guidelines\/032-045OLl_S3_Mammakarzinom_2021-07.pdf. Accessed 26.03.24"},{"key":"5936_CR68","doi-asserted-by":"publisher","first-page":"2366","DOI":"10.1158\/1055-9965.EPI-10-0162","volume":"19","author":"T Saxena","year":"2010","unstructured":"Saxena T, Lee E, Henderson KD, Clarke CA, West D, Marshall SF, Deapen D, Bernstein L, Ursin G (2010) Menopausal hormone therapy and subsequent risk of specific invasive breast cancer subtypes in the California Teachers Study. Cancer Epidemiol Biomarkers Prev 19:2366\u20132378. https:\/\/doi.org\/10.1158\/1055-9965.EPI-10-0162","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"5936_CR69","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1001\/jama.283.4.485","volume":"283","author":"C Schairer","year":"2000","unstructured":"Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, Hoover R (2000) Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA 283:485\u2013491. https:\/\/doi.org\/10.1001\/jama.283.4.485","journal-title":"JAMA"},{"key":"5936_CR70","doi-asserted-by":"publisher","first-page":"023","DOI":"10.1093\/jncics\/pky023","volume":"2","author":"LH Schrijver","year":"2018","unstructured":"Schrijver LH, Olsson H, Phillips K-A, Terry MB, Goldgar DE, Kast K, Engel C, Mooij TM, Adlard J, Barrowdale D, Davidson R, Eeles R, Ellis S, Evans DG, Frost D, Izatt L, Porteous ME, Side LE, Walker L, Berthet P, Bonadona V, Leroux D, Mouret-Fourme E, Venat-Bouvet L, Buys SS, Southey MC, John EM, Chung WK, Daly MB, Bane A, van Asperen CJ, G\u00f3mez Garcia EB, Mourits MJE, van Os TAM, Roos-Blom M-J, Friedlander ML, McLachlan S-A, Singer CF, Tan YY, Foretova L, Navratilova M, Gerdes A-M, Caldes T, Simard J, Olah E, Jakubowska A, Arver B, Osorio A, Nogu\u00e8s C, Andrieu N, Easton DF, van Leeuwen FE, Hopper JL, Milne RL, Antoniou AC, Rookus MA (2018) Oral contraceptive use and breast cancer risk: retrospective and prospective analyses from a BRCA1 and BRCA2 mutation carrier cohort study. JNCI Cancer Spectr. 2:023. https:\/\/doi.org\/10.1093\/jncics\/pky023","journal-title":"JNCI Cancer Spectr."},{"key":"5936_CR71","doi-asserted-by":"publisher","first-page":"51.e1","DOI":"10.1016\/j.ajog.2021.01.014","volume":"225","author":"LH Schrijver","year":"2021","unstructured":"Schrijver LH, Antoniou AC, Olsson H, Mooij TM, Roos-Blom M-J, Azarang L, Adlard J, Ahmed M, Barrowdale D, Davidson R, Donaldson A, Eeles R, Evans DG, Frost D, Henderson A, Izatt L, Ong K-R, Bonadona V, Coupier I, Faivre L, Fricker J-P, Gesta P, van Engelen K, Jager A, Menko FH, Mourits MJE, Singer CF, Tan YY, Foretova L, Navratilova M, Schmutzler RK, Ellberg C, Gerdes A-M, Caldes T, Simard J, Olah E, Jakubowska A, Rantala J, Osorio A, Hopper JL, Phillips K-A, Milne RL, Beth Terry M, Nogu\u00e8s C, Engel C, Kast K, Goldgar DE, van Leeuwen FE, Easton DF, Andrieu N, Rookus MA (2021) Oral contraceptive use and ovarian cancer risk for BRCA1\/2 mutation carriers: an international cohort study. Am J Obstet Gynecol 225:51.e1-51.e17. https:\/\/doi.org\/10.1016\/j.ajog.2021.01.014","journal-title":"Am J Obstet Gynecol"},{"key":"5936_CR72","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1093\/jnci\/djac004","volume":"114","author":"LH Schrijver","year":"2022","unstructured":"Schrijver LH, Mooij TM, Pijpe A, Sonke GS, Mourits MJE, Andrieu N, Antoniou AC, Easton DF, Engel C, Goldgar D, John EM, Kast K, Milne RL, Olsson H, Phillips K-A, Terry MB, Hopper JL, van Leeuwen FE, Rookus MA (2022) Oral contraceptive use in BRCA1 and BRCA2 mutation carriers: absolute cancer risks and benefits. J Natl Cancer Inst 114:540\u2013552. https:\/\/doi.org\/10.1093\/jnci\/djac004","journal-title":"J Natl Cancer Inst"},{"key":"5936_CR73","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.ygyno.2013.03.027","volume":"130","author":"Y Segev","year":"2013","unstructured":"Segev Y, Iqbal J, Lubinski J, Gronwald J, Lynch HT, Moller P, Ghadirian P, Rosen B, Tung N, Kim-Sing C, Foulkes WD, Neuhausen SL, Senter L, Singer CF, Karlan B, Ping S, Narod SA (2013) The incidence of endometrial cancer in women with BRCA1 and BRCA2 mutations: an international prospective cohort study. Gynecol Oncol 130:127\u2013131. https:\/\/doi.org\/10.1016\/j.ygyno.2013.03.027","journal-title":"Gynecol Oncol"},{"key":"5936_CR74","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s10689-015-9798-8","volume":"14","author":"Y Segev","year":"2015","unstructured":"Segev Y, Rosen B, Lubinski J, Gronwald J, Lynch HT, Moller P, Kim-Sing C, Ghadirian P, Karlan B, Eng C, Gilchrist D, Neuhausen SL, Eisen A, Friedman E, Euhus D, Ping S, Narod SA (2015) Risk factors for endometrial cancer among women with a BRCA1 or BRCA2 mutation: a case control study. Fam Cancer 14:383\u2013391. https:\/\/doi.org\/10.1007\/s10689-015-9798-8","journal-title":"Fam Cancer"},{"key":"5936_CR75","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1093\/humupd\/dmt034","volume":"20","author":"TN Sergentanis","year":"2014","unstructured":"Sergentanis TN, Diamantaras A-A, Perlepe C, Kanavidis P, Skalkidou A, Petridou ET (2014) IVF and breast cancer: a systematic review and meta-analysis. Hum Reprod Update 20:106\u2013123. https:\/\/doi.org\/10.1093\/humupd\/dmt034","journal-title":"Hum Reprod Update"},{"key":"5936_CR76","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1001\/jamaoncol.2016.1820","volume":"2","author":"CA Shu","year":"2016","unstructured":"Shu CA, Pike MC, Jotwani AR, Friebel TM, Soslow RA, Levine DA, Nathanson KL, Konner JA, Arnold AG, Bogomolniy F, Dao F, Olvera N, Bancroft EK, Goldfrank DJ, Stadler ZK, Robson ME, Brown CL, Leitao MM, Abu-Rustum NR, Aghajanian CA, Blum JL, Neuhausen SL, Garber JE, Daly MB, Isaacs C, Eeles RA, Ganz PA, Barakat RR, Offit K, Domchek SM, Rebbeck TR, Kauff ND (2016) Uterine cancer after risk-reducing salpingo-oophorectomy without hysterectomy in women with BRCA mutations. JAMA Oncol 2:1434\u20131440. https:\/\/doi.org\/10.1001\/jamaoncol.2016.1820","journal-title":"JAMA Oncol"},{"key":"5936_CR77","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1093\/humupd\/dms051","volume":"19","author":"C Siristatidis","year":"2013","unstructured":"Siristatidis C, Sergentanis TN, Kanavidis P, Trivella M, Sotiraki M, Mavromatis I, Psaltopoulou T, Skalkidou A, Petridou ET (2013) Controlled ovarian hyperstimulation for IVF: impact on ovarian, endometrial and cervical cancer\u2013a systematic review and meta-analysis. Hum Reprod Update 19:105\u2013123. https:\/\/doi.org\/10.1093\/humupd\/dms051","journal-title":"Hum Reprod Update"},{"key":"5936_CR78","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1080\/0284186X.2016.1175660","volume":"55","author":"T Soini","year":"2016","unstructured":"Soini T, Hurskainen R, Gr\u00e9nman S, M\u00e4enp\u00e4\u00e4 J, Paavonen J, Pukkala E (2016) Impact of levonorgestrel-releasing intrauterine system use on the cancer risk of the ovary and fallopian tube. Acta Oncol 55:1281\u20131284. https:\/\/doi.org\/10.1080\/0284186X.2016.1175660","journal-title":"Acta Oncol"},{"key":"5936_CR79","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1016\/S0140-6736(98)05066-1","volume":"352","author":"L Sourander","year":"1998","unstructured":"Sourander L, Rajala T, R\u00e4ih\u00e4 I, M\u00e4kinen J, Erkkola R, Helenius H (1998) Cardiovascular and cancer morbidity and mortality and sudden cardiac death in postmenopausal women on oestrogen replacement therapy (ERT). Lancet 352:1965\u20131969. https:\/\/doi.org\/10.1016\/S0140-6736(98)05066-1","journal-title":"Lancet"},{"key":"5936_CR80","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1002\/ijc.20016","volume":"109","author":"C Stahlberg","year":"2004","unstructured":"Stahlberg C, Pedersen AT, Lynge E, Andersen ZJ, Keiding N, Hundrup YA, Obel EB, Ottesen B (2004) Increased risk of breast cancer following different regimens of hormone replacement therapy frequently used in Europe. Int J Cancer 109:721\u2013727. https:\/\/doi.org\/10.1002\/ijc.20016","journal-title":"Int J Cancer"},{"key":"5936_CR81","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12082195","author":"CB Tempfer","year":"2020","unstructured":"Tempfer CB, Hilal Z, Kern P, Juhasz-Boess I, Rezniczek GA (2020) Menopausal hormone therapy and risk of endometrial cancer: a systematic review. Cancers. https:\/\/doi.org\/10.3390\/cancers12082195","journal-title":"Cancers"},{"key":"5936_CR82","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1093\/jnci\/94.18.1358","volume":"94","author":"D Thompson","year":"2002","unstructured":"Thompson D, Easton DF (2002) Cancer Incidence in BRCA1 mutation carriers. J Natl Cancer Inst 94:1358\u20131365. https:\/\/doi.org\/10.1093\/jnci\/94.18.1358","journal-title":"J Natl Cancer Inst"},{"key":"5936_CR83","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1002\/cncr.20250","volume":"100","author":"A Tj\u00f8nneland","year":"2004","unstructured":"Tj\u00f8nneland A, Christensen J, Thomsen BL, Olsen A, Overvad K, Ewertz M, Mellemkjaer L (2004) Hormone replacement therapy in relation to breast carcinoma incidence rate ratios: a prospective Danish cohort study. Cancer 100:2328\u20132337. https:\/\/doi.org\/10.1002\/cncr.20250","journal-title":"Cancer"},{"key":"5936_CR84","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1093\/humupd\/dmac038","volume":"29","author":"MHD van Bommel","year":"2023","unstructured":"van Bommel MHD, IntHout J, Veldmate G, Kets CM, de Hullu JA, van Altena AM, Harmsen MG (2023) Contraceptives and cancer risks in BRCA1\/2 pathogenic variant carriers: a systematic review and meta-analysis. Hum Reprod Update 29:197\u2013217. https:\/\/doi.org\/10.1093\/humupd\/dmac038","journal-title":"Hum Reprod Update"},{"key":"5936_CR85","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1001\/jama.2016.9389","volume":"316","author":"AW van den Belt-Dusebout","year":"2016","unstructured":"van den Belt-Dusebout AW, Spaan M, Lambalk CB, Kortman M, Laven JSE, van Santbrink EJP, van der Westerlaken LAJ, Cohlen BJ, Braat DDM, Smeenk JMJ, Land JA, Goddijn M, van Golde RJT, van Rumste MM, Schats R, J\u00f3zwiak K, Hauptmann M, Rookus MA, Burger CW, van Leeuwen FE (2016) Ovarian stimulation for in vitro fertilization and long-term risk of breast cancer. JAMA 316:300\u2013312. https:\/\/doi.org\/10.1001\/jama.2016.9389","journal-title":"JAMA"},{"key":"5936_CR86","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1359\/JBMR.040215","volume":"19","author":"M van der Klift","year":"2004","unstructured":"van der Klift M, de Laet CEDH, McCloskey EV, Johnell O, Kanis JA, Hofman A, Pols HAP (2004) Risk factors for incident vertebral fractures in men and women: the Rotterdam study. J Bone Miner Res 19:1172\u20131180. https:\/\/doi.org\/10.1359\/JBMR.040215","journal-title":"J Bone Miner Res"},{"key":"5936_CR87","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/0378-5122(94)90061-2","volume":"19","author":"EM Vega","year":"1994","unstructured":"Vega EM, Egea MA, Mautalen CA (1994) Influence of the menopausal age on the severity of osteoporosis in women with vertebral fractures. Maturitas 19:117\u2013124. https:\/\/doi.org\/10.1016\/0378-5122(94)90061-2","journal-title":"Maturitas"},{"key":"5936_CR88","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1080\/13697137.2017.1285879","volume":"20","author":"RFM Vermeulen","year":"2017","unstructured":"Vermeulen RFM, van Beurden M, Korse CM, Kenter GG (2017) Impact of risk-reducing salpingo-oophorectomy in premenopausal women. Climacteric 20:212\u2013221. https:\/\/doi.org\/10.1080\/13697137.2017.1285879","journal-title":"Climacteric"},{"key":"5936_CR89","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1056\/NEJMoa010534","volume":"345","author":"CM Viscoli","year":"2001","unstructured":"Viscoli CM, Brass LM, Kernan WN, Sarrel PM, Suissa S, Horwitz RI (2001) A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med 345:1243\u20131249. https:\/\/doi.org\/10.1056\/NEJMoa010534","journal-title":"N Engl J Med"},{"key":"5936_CR90","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/BF00052671","volume":"7","author":"DB Willis","year":"1996","unstructured":"Willis DB, Calle EE, Miracle-McMahill HL, Heath CW (1996) Estrogen replacement therapy and risk of fatal breast cancer in a prospective cohort of postmenopausal women in the United States. Cancer Causes Control 7:449\u2013457. https:\/\/doi.org\/10.1007\/BF00052671","journal-title":"Cancer Causes Control"},{"key":"5936_CR91","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.ygyno.2022.01.014","volume":"164","author":"YY Xia","year":"2022","unstructured":"Xia YY, Gronwald J, Karlan B, Lubinski J, McCuaig JM, Brooks J, Moller P, Eisen A, Sun S, Senter L, Bordeleau L, Neuhausen SL, Singer CF, Tung N, Foulkes WD, Sun P, Narod SA, Kotsopoulos J (2022) Contraceptive use and the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation. Gynecol Oncol 164:514\u2013521. https:\/\/doi.org\/10.1016\/j.ygyno.2022.01.014","journal-title":"Gynecol Oncol"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-024-05936-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-024-05936-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-024-05936-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T15:16:02Z","timestamp":1728486962000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-024-05936-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,11]]},"references-count":92,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,9]]}},"alternative-id":["5936"],"URL":"https:\/\/doi.org\/10.1007\/s00432-024-05936-7","relation":{},"ISSN":["1432-1335"],"issn-type":[{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,11]]},"assertion":[{"value":"31 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Financial interests: O.O.: O.O. has received speaker honorarium from AstraZeneca; Astellas Pharma; Novartis Pharma and ownes stocks of Novartis, Bayer, Fresenius Medical Care, Curevac, Morphosys S.S.-T.: SST received speaker honorarium from Pfizer, Roche and author honorarium from thieme and further training was supported by GSK and Celgene K.K.: Honorary, advisory board, Pfizer Pharma Non-financial interests: O.O.: Memberships: Member of the Board of the German Cancer Society, Board of Trustees of German Cancer Aid, Member of the Board of ADT; Memberships of professional associations: German Society for Gynecology and Obstetrics\u2014Gynecological Oncology Working Group, Kommission OVAR; German Society for Senology; German Society for Endocrinology; Working Group for Gynecologic Oncology; German Cancer Society; Bavarian Cancer Society; Bavarian Society for Obstetrics and Gynecology; Coordinator of the S3 guideline \u201cPeri- and Postmenopause\u2014Diagnostics and Interventions\u201d; Mandate holder for the DKG Certification Commission for Gynecological Cancer Centers S.S.-T.: SST is Member of the Working Group for Cervical Pathology and Colposcopy (AG-CPC); Member of the German Society for Gynecology and Obstetrics (DGGG); Member of the Working Group for Gynecologic Oncology (AGO) and the Kommission OVAR and Member of the German Cancer Society (DKG) K.K.: none.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This is a systematic review. No ethical approval is required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"417"}}